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Abstract
Background: Human papillomavirus (HPV) causes cervical cancer and external genital warts. The
purpose of this study is to document the genotype distribution of HPV in females aged between 18
and 34 who self-referred to an STI clinic with visible external genital warts (EGW). Scrapings were
taken from visible external genital warts (EGW). These scrapings were analysed by PCR for the
presence of HPV DNA. Positive samples were then genotyped by means of a commercially available
assay (LiPA). A comparison of genotyping results determined by the LiPA assay and direct amplicon
DNA sequencing was also performed.
Results: Ninety-two patients out of 105 samples (88%) had detectable levels of HPV DNA. The
majority of individuals with EGW (66%) showed the presence of two or more genotypes. The most
common HPV genotypes present in the study population were HPV-6, HPV-11, HPV-16, HPV-18,
HPV-33 and HPV-53. Potential effects of vaccination on HPV molecular epidemiology indicate that
40% of the patients could have been protected from the high risk genotypes HPV-16 and HPV-18.
Conclusion: This is the first report of the molecular epidemiology of external genital warts in
women aged between 18 and 34 from Ireland based on results from a LiPA assay. The study shows
that most individuals are infected with multiple genotypes including those with high oncogenic
potential and that the newly available HPV vaccines could have a significant impact on prevalence
of the most common HPV genotypes in this study population.
Background
Human papillomavirus (HPV) is a group of non-envel-
oped DNA viruses, which cause benign and malignant
epithelial lesions [1]. Over a hundred different HPV gen-
otypes have been characterized and of these more than
50% cause external genital warts (EGW) [2]. Ninety per-
cent of EGW are reported to be of oncogenic potential,
constituting genotypes 6 and 11 [3]. The majority of HPV
infections are self-limiting. However, a potential long
term effect of HPV infection is its association with precan-
cerous histological lesions such as cervical intra-epithelial
neoplasia 3 (CIN3) or carcinoma in situ (CIS). HPV is a
necessary causative agent of cervical cancer, with HPV
DNA detectable in 99.7% of cervical cancer specimens [4].
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such as types HPV-16, HPV-18 and HPV-31. HPV-16
alone is responsible for 58.9% of all cervical cancers [5].
Cervical cancer is the second commonest cause of cancer
deaths in women worldwide. In the U.S alone the cost of
preventing and treating cervical cancer exceeds $5 billion
per year [6]. Cervical screening has greatly reduced the
incidence of cervical cancer in the developed world [7].
An exciting advancement in cervical cancer prevention is
the recent development of two HPV vaccines. A quadriva-
lent vaccine (Gardasil, Merck) against the four most med-
ically significant HPV genotypes (6/11 and 16/18), which
cause 90% of external genital warts and 70% of cervical
cancers respectively was approved by the Food and Drug
Administration (FDA) in June 2006 [8]. A bivalent vaccine
(Cervarix, GlaxoSmithKline Biologicals) against HPV-16
and HPV-18 is licensed for use in Europe and it has shown
potential cross protection against the high risk genotypes
HPV-45 and HPV-31 [9,10]. As these vaccines become
more widely used information on the molecular epidemi-
ology of HPV in Ireland will be important to determine
efficacy and the potential for cross genotype protection. It
is likely that genotype displacement will occur as herd
immunity increases.
The molecular epidemiology of external genital warts
[EGWs] in Irish females has not been studied but likely
reflects that of other European countries. The prevalence
and nature of the mixed genotype infections in this popu-
lation is also unknown. PCR combined with reverse line
probe hybridisation (RLPH) is a fast and sensitive method
of genotyping viral infections. The routine use of these
assays allows a more thorough analysis of HPV molecular
epidemiology and assessment of likely cervical cancer risk.
The study group presented here was collated through a
voluntary screening program for females, aged between
18 and 34, who self presented to an STI clinic in Southern
Ireland. Scrapings from EGW were taken and tested by
PCR for HPV DNA; positive samples were genotyped
using a commercially available RLPH assay. The DNA
sequence of the preliminary amplicon was also deter-
mined for the first 52 patients. The results of this screening
programme provide information on the frequency of sex-
ually transmitted HPV strains circulating in a sample of
the Irish population.
Results
Detection of HPV by Real-Time PCR
To determine the presence of HPV, DNA from 114 consec-
utive samples was applied to a SYBR Green I assay utilis-
ing MY09-MY-11 degenerate primers. To ascertain the
sensitivity of the assay a serial dilution of genomic DNA
known to have integrated HPV-16 viral DNA was per-
formed (CaSki HTC98018). The assay was capable of
detecting 30 copies of HPV DNA per amplification. 92
samples were found to be positive by HPV PCR using this
method. Nine of the 114 samples were blinded negative
controls. Therefore, taking the blinded controls into
account, 92 out of 105 samples were HPV positive.
In total, 21 different genotypes were recorded; 6, 11, 16,
18, 31, 33, 35, 39, 40, 45, 51, 52, 53, 55, 56, 58, 59, 66,
68, 70 and 74. These genotypes account for approximately
90% of the 17 genotypes identified as high risk or proba-
ble high risk for cervical cancer according [5]. The only
two high or probable high risk genotypes not identified in
this study population were genotypes 82 and 26 [5].
Thirty-one (34%) of the HPV positive patients were found
to have a single HPV genotype, 97% of which were either
genotype 6 or 11 (Table 1). The multiplicity of genotype
infection is outlined in Figure 1. The most prevalent gen-
otypes were HPV-16 (n = 15), HPV-18 (n = 20), HPV-31
(n = 8) and HPV-33 (n = 9) (Table 1). The maximum
number of HPV genotypes detected in a single patient was
8, n = 2. Genotype 6 and genotype 11 were present in 62%
and 35% of the 92 positive samples respectively (Table 1).
Genotypes 6, 11 and 18 were present in the majority of
dual infections. Triple infections comprised of genotype
6, 11, 16, 18 and 66 (Table 1). Other common genotypes
were 39 (n = 5), 51 (n = 18), 52 (n = 8) and 53 (n = 18).
The LiPA assay also confirmed that 4 patients were co-
infected with both HPV-16 and HPV-18 genotypes.
Genotyping of HPV based on Sequence analysis
52 of the 92 HPV positive samples were genotyped by
direct DNA sequencing of the positive PCR product. 72%
of samples were identified as having either genotypes 6 or
11; 29 samples were positive for HPV-6, 13 samples were
positive for HPV-11. Only 2 samples were positive by
DNA sequence analysis for HPV-16. An additional 2 sam-
ples were positive for genotype 18. Other genotypes
detected were 33, 39, and 53 at a frequency of 3/52, 1/52
and 2/52, respectively.
Discussion
The primary aim of this study was to ascertain for the first
time the molecular epidemiology of sexually transmitted
HPV in EGW. This genotype information should assist in
estimating the potential benefits of the newly available
HPV vaccines and highlight the importance of multiple
infections.
DNA was successfully extracted from a limited scraping of
externally visible EGW using an automated DNA extrac-
tion system. The potential falsenegative rate for this study
was 12% (13/105). A possible explanation is that insuffi-
cient DNA was present to generate an amplicon or the
MY09-11 primer set, used in the initial screening for HPV
positivity, may be sub-optimal for specific genotypes.Page 2 of 6
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that a total of 15 out of a possible 17 high or probably
high risk genotypes were detected with this methodologi-
cal approach. Of the panel of high or probably high risk
genotypes proposed by Meyer et al only two relatively
uncommon genotypes, i.e., 82 and 26, were not identified
in the study population [5]. Another commonly used set
of PCR primers used to amplify HPV is the PGMY09-11
primer set. Given the epidemiological coverage provided
by the MY09-MY11 generic primers it is unlikely that
additional significant genotype coverage would be pro-
vided by use of the PGMY09-11 primer combination [11].
The combination of the real-time and automated DNA
extraction allowed for a fast sample throughput (t = 5
hours). In 100% of cases (n = 52) DNA sequencing
revealed an equivalent genotype when compared to the
LiPA assay. Nevertheless DNA sequencing using consen-
sus primers doesn't readily enable the detection of multi-
ple infections [12]. DNA sequencing with consensus
primers likely reflects relative viral load with regard to the
dominance of a genotype in the mixed genotype popula-
tion. This feature likely affects all PCR based DNA
sequencing methodologies and is not specific to the
MY09-MY-11 primers used in this study. Recently, Matsu-
kura et al., 2008 questioned the validity of using PCR and
sequencing to determine HPV genotypes especially those
associated with cervical cancer [13]. Our results would
support Matsukura's inferences.
The combination of real-time PCR and LiPA assay identi-
fied low risk genotypes 6 and 11 or both in 88% of EGWs
tested. This trend is evident in HPV infections worldwide
as 90% of all genital warts are related to types 6 and 11
[14]. In spite of this, a clinically important detail revealed
by this study was that 66% of all EGW contained multiple
genotypes. Only 30/92 (30%) of the patients were
infected with a low risk genotype(s). The remainder of the
patients studied were infected with at least one high or
probable risk HPV (Table 1).
HPV-16, HPV-18 and HPV-31 which account for 75% of
cervical cancers [1] were prevalent in our study popula-
tion at a combined frequency of 39% (n = 36). Although
the tissue genotyped was external to the cervix, the pres-
ence of high risk genotypes in EGWs is a matter of concern
and merits a thorough examination of the patient for cer-
vical lesions and HPV genotyping of the cervix [15]. The
current dogma regarding the inherent risk of HPV infec-
tion and EGW is that in 90% of patients, the HPV geno-
type present is associated with a low risk of progression to
cervical cancer. The findings presented in this study indi-
cate that all HPV should be genotyped by LiPA or another
form of reverse line probe hybridisation, as there is a sig-
nificant risk that oncogenic genotypes may be present in a
co-infection scenario. The presence of oncogenic HPV in
EGW raises the possibility that this infection site is a
source of HPV that may infect the cervix. The correlation
between the presence of multiple genotype infections in
EGW and the genotype epidemiology in the epidermal tis-
sue of the cervix is incompletely defined at present.
The optimum time for vaccination with the new HPV vac-
cine (subject to the duration of immune protection) is rec-
ognised to be at the onset of puberty [16]. Both the
bivalent and quadrivalent vaccine could have prevented
34 patients (37%) from contracting HPV-16 and/or HPV-
18. If the potential cross protection associated with the
bivalent vaccine is taken into account, a further 14
patients would not have contracted either HPV 45 (n = 7)
and/or HPV 31 (n = 8) (Table 1) [10]. One patient was co-
infected with both genotypes 45 and 31, specimen ID 31.
Conclusion
This study identifies for the first time the molecular epide-
miology of HPV in the EGWs of young Irish women. The
results of the study found that the majority of EGWs con-
tained the low risk genotypes 6 and 11. Despite this, a
large number 70% of the patients were co-infected with
one or more high risk genotypes. The new HPV vaccines
would have prevented a significant number of these
patients from contracting HPV or provided protection
against the most oncogenic HPV genotypes 16, 18 and 31.
It is to be presumed that with sufficient usage of these vac-
cines that genotype replacement will become a feature of
the epidemiology of HPV infection.
Methods
Ethical approval
The study outlined here was approved by the Clinical
Research Ethics Committees of the Cork teaching Hospi-
Observed multiplicity of HPV genotype infection in external genital wartsFigure 1
Observed multiplicity of HPV genotype infection in 
external genital warts.
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within the study was voluntary and patients gave
informed consent before entry into the study.
Study population
Between October 2006 and October 2008 samples were
taken from 114 females who self referred to an STI clinic
in Cork, Ireland. The age of the patients ranged from 19–
34 years of age with an average age of 24.
Samples
Scrapings were taken from visible external genital warts of
the patients using small brushes. The brushes were stored
at room temperature in 500 μl of Lysis Binding buffer
(LBB) from the ROCHE™ MagNa Pure LC Total Nucleic
Acid isolation Kit. Samples were received from the clini-
cian in a blinded manner. 9 random negative samples
were included and the knowledge of these and individual
patient status was kept hidden from the diagnostic labora-
Table 1: Profile of HPV genotypes in infected patients.
Specimen ID Genotype profile Specimen ID Genotype profile
1* 6 47* 6, 18
2 6, 66, 40 48 6, 16, 53
3 6,11,51,53 49* 6
4* 6 50* 6
5* 11 51 11, 35
6 11, 55 52 11, 45
7 39 53* 6
8 6, 18, 31, 33, 51, 66, 68, 70 54* 6
9 6, 51, 66 55 6, 39, 66
10 11, 16, 66 56* 6
11 6, 11, 52, 53, 68 57* 6
12 6, 18, 33, 39, 52 58 6, 51
13* 11 59 11, 51, 53
14 11, 53 60 11, 18, 52, 53, 59, 70
15 31, 33, 53, 56 61 11, 16, 52, 74
16 6, 31, 51, 66, 68 62 11, 16, 51, 66
17 6, 59 63 6, 18, 31
18 6, 53 64 11, 51, 53
19* 11 65 6, 33, 39, 51, 53
20 6, 11, 66 66* 6,16,18
21 6, 45, 52, 53 67 18, 70
22* 6 68* 6
23* 6 69* 6, 11
24* 11 70 6, 16
25* 6, 18 71* 6
26 18, 53 72* 6
27* 6 73* 16
28 33 74* 11
29 6, 51, 66 75 18, 51, 53
30* 11 76* 11
31 6, 11, 40, 31, 45, 53, 70 77 16, 45, 59
32* 6, 16, 18 78 40
33 16, 33, 35, 51, 52 79 6, 18, 31, 53
34* 6 80 6, 16, 53
35* 11, 16 81* 6
36* 6, 18 82 16, 18, 58
37* 6, 18 83* 11
38* 6, 11 84 6, 18, 53, 68, 70
39 6, 11, 31, 33, 35, 39 85 18, 45
40* 6 86 6, 51
41 6, 31, 33, 40, 52, 53, 58, 68 87* 6
42 6, 11, 51 88* 6
43 6, 18, 45 89 16, 18, 51, 45
44* 6. 11 90 11, 18, 51
45 11, 51 91 11, 51, 52
46 11, 59 92 6, 16, 33
* indicates patients who may have been protected from a HPV infection by the quadrivalent vaccine.Page 4 of 6
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study completion sample identities were revealed.
Viral DNA extraction
300 μl of sample HPV-LBB was added to 200 μl of nucle-
ase free water and applied to the MagNa Pure LC Total
Nucleic acid isolation Kit using the Roche Magna Pure
Robotic extraction machine, yielding 50 μl of extracted
DNA. A negative control consisting of water was included
with every extraction.
HPV detection
HPV positive samples were detected by real time PCR
using My09-MY-11 generic primers [17] and SYBR Green
I chemistry. Briefly, 5 μl of extracted DNA was applied to
a 12.5 μl of SYBR green jumpstart Taq ReadyMix™ (Sigma
Aldrich), 0.5 μl each of Primer (10 μM) and 6.5 μl of
nuclease free water, yielding a final volume of 25 μl. The
reaction was performed on an ABI 7500 thermocycler
using the following conditions, 95°C 3 min followed by
40 cycles of 95°C for 15 s, 55°C for 1 min and 72°C for
1 min 30 s with a fluorescence read step every cycle at
72°C. Positive samples were verified using a dissociation
curve which gave melting peaks of the positive PCR prod-
ucts between 80 – 82°C. The negative control included in
the DNA extraction was included in the real time PCR.
Sensitivity of SYBR Green I PCR assay
To ascertain the sensitivity of the assay serial dilutions of
commercially available genomic DNA from the CaSki cell
line (HTC98018) containing 600 copies of HPV16/
genome were generated. A standard curve was created
where DNA from the CaSki cell line with a range of
300,000, serially diluted by a factor of 10, to a final con-
centration of 3 copies per PCR. The dilutions are then
applied in 5 μl volumes to the Real-time assay described
above to create a standard curve.
Genotyping of positive HPV samples
Positive samples were amplified using Biotin labelled
primers provided in the INNOGENTICS HPV genotyping
assay (Gent, Belgium). A no template control was per-
formed with every biotinylated PCR to ensure no cross
contamination was occurring during pre-amplification
stage or during the automated process. 15 μl of each
biotin labelled PCR product including the negative con-
trol was then applied to a disposable line probe strip pro-
vided and placed in an AuoLipA 30 and Reverse Line
Probe Hybridisation was performed at an annealing tem-
perature of 49°C using the HCVV3 programme. Interpre-
tation of the genotype of the positive samples was
performed using the key provided with the kit. The kit can
detect the following genotypes 6, 11, 16, 18, 31, 33, 40,
45, 51, 53, 54, 58, 59, 66, 68, 70 (n = 16). In cases where
the CE marked LiPA assay could not resolve the exact gen-
otype of HPV present, the sample was applied to a second
LiPA assay (version 2). The HPV LiPA version 2 assay can
detect the following genotypes 6, 11, 16, 18, 31/54, 33,
35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 56/74, 58, 59, 66,
68/73, 70 (n = 24). The HPV LiPA Extra assay became
available towards the end of the study. This assay covers
all currently known high-risk HPV genotypes and proba-
ble high-risk HPV genotypes (16, 18, 26, 31, 33, 35, 39,
45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82) as well as a
number of low-risk HPV genotypes (6, 11, 40, 43, 44, 54,
70) and some additional types (69, 71, 74).
All these assays carry a CE mark which means the assays
meet European union stringent quality controls in terms
of sensitivity and reproducibility. Where confounding
genotype heterozygosity was observed the potential geno-
types were excluded from the analysis for this individual.
Where the CE LiPA assay could not resolve the genotype
present the sample was applied to the LiPA V2 assay or the
LiPA extra assay.
DNA sequence analysis
The PCR amplicons of the first 60 positive samples were
purified using the High Pure PCR product purification kit
(Roche) and air dried PCR products were outsourced to
MWG (Ebersberg, Germany) for DNA sequencing.
Sequencing was performed using the MY-11 primer. Fifty-
two samples were successfully sequenced and these were
analysed by submitting the obtained DNA sequence to the
BLASTn programme available at Genbank. http://
www.ncbi.nlm.nih.gov/BLAST. All sequences were sub-
mitted to the Genbank database and accession numbers
were acquired for this study (EU056593–EU056644).
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